Familial adenomatous polyposis (FAP) is caused by germ-line mutations of the apc gene, and it is associated with an increased risk of developing papillary thyroid carcinomas. We have previously reported that a significant fraction of sporadic human papillary thyroid carcinomas is characterized by gene rearrangements affecting the ret protooncogene. These rearrangements generate chimeric transforming oncogenes designated ret/ptc. By a combined immunohistochemical and RT-PCR approach, we analyzed, for ret/ptc oncogene activation, papillary thyroid carcinomas occurred in two FAP kindreds, both showing typical apc gene mutations. Kindred 1 had seven members affected by FAP, and among these, three patients showed papillary thyroid carcinomas. Kindred 2 had two patients, mother and daughter, affected by colonic polyposis; the 20-yr-old daughter showed also a papillary carcinoma. Here we report that ret/ptc1 oncogene was activated in two of the three papillary carcinomas of FAP kindred 1 and in the papillary carcinoma of FAP kindred 2. These findings document that loss of function of apc coexists with gain of function of ret in some papillary thyroid carcinomas, suggesting that ret/ptc1 oncogene activation could be a progression step in the development of FAP-associated thyroid tumors. (J Clin Endocrinol Metab 83: [1003][1004][1005][1006] 1998) F AMILIAL adenomatous polyposis (FAP) is an autosomal dominant precancerous condition of the colon that is caused by mutations of the tumor suppressor apc gene (1-3). FAP patients often develop extracolonic manifestations, including osteomas and brain tumors, and a review of the world literature indicated that a total of 63 FAP patients showed the development of thyroid carcinomas (4). Moreover, an analysis of the largest existing FAP register indicated that about 1% of patients with FAP showed thyroid differentiated carcinomas (5, 6). FAP-associated thyroid carcinomas are currently considered a distinct type of follicular cell neoplasms because of the age of these patients, which is relatively young (range, 16 -40 yr) (7), the morphological features, and the excellent prognosis (4, 8).
among these, three patients showed papillary thyroid carcinomas. Kindred 2 had two patients, mother and daughter, affected by colonic polyposis; the 20-yr-old daughter showed also a papillary carcinoma. Here we report that ret/ptc1 oncogene was activated in two of the three papillary carcinomas of FAP kindred 1 and in the papillary carcinoma of FAP kindred 2. These findings document that loss of function of apc coexists with gain of function of ret in some papillary thyroid carcinomas, suggesting that ret/ptc1 oncogene activation could be a progression step in the development of FAP-associated thyroid tumors. (J Clin Endocrinol Metab 83: 1003-1006, 1998) F AMILIAL adenomatous polyposis (FAP) is an autosomal dominant precancerous condition of the colon that is caused by mutations of the tumor suppressor apc gene (1) (2) (3) . FAP patients often develop extracolonic manifestations, including osteomas and brain tumors, and a review of the world literature indicated that a total of 63 FAP patients showed the development of thyroid carcinomas (4). Moreover, an analysis of the largest existing FAP register indicated that about 1% of patients with FAP showed thyroid differentiated carcinomas (5, 6) . FAP-associated thyroid carcinomas are currently considered a distinct type of follicular cell neoplasms because of the age of these patients, which is relatively young (range, 16 -40 yr) (7), the morphological features, and the excellent prognosis (4, 8) .
Thyroid differentiated cancer comprises follicular and papillary histotypes, which greatly differ in terms of risk factors, pathogenetic mechanisms, and biological behaviors (9 -11) . In fact, the former is more frequent in areas with iodine deficiency and frequently shows activation of ras family oncogenes; the latter is more frequent after exposure to fall-out radiation and frequently shows ret/ptc oncogene activation (between 25-40% of the cases) (12) (13) (14) (15) . Three ret/ptc isoforms are known and are designated ret/ptc1, ret/ptc2, and ret/ptc3. These oncogenes derive from gene rearrangements affecting the RET gene, which encodes a receptor-type tyrosine kinase for neurotropic molecules belonging to the glial cell-line derived neurotropic factor (GDNF) family (16, 17) . A gene named H4 (or D10S170) is rearranged with ret in the case of ret/ptc1 (18) . The 5Ј-portion of ret/ptc2 is represented by the gene encoding the regulatory subunit RI of the protein kinase A (19) . Finally, in the case of ret/ptc3, the fusion of ret occurs with the rfg gene (20) .
We have recently described the pedigree and clinical data of a FAP family in which three patients (two sisters and one maternal aunt), in addition to adenomatous polyposis, developed thyroid papillary carcinomas (21) . Subsequently, we identified another FAP kindred, a member of which also developed a papillary thyroid carcinoma. Here we report that three of these four papillary carcinomas are characterized by activation of the ret/ptc1 oncogene.
Subjects and Methods Patients
Fifteen FAP families had intensive screening for associated extracolonic manifestations (Cetta, F., et al., unpublished results). All patients underwent ultrasound examination of the thyroid gland; ultrasoundguided fine needle agobiopsy of all of the nodules larger than 5 mm was performed, followed by cytological examination of the specimen. Two families showed at least 1 member affected by thyroid carcinoma. Kindred 1 consisted of 23 members throughout 4 generations. Seven members of the last 2 generations were affected by FAP. Three patients of this kindred, 2 daughters, aged 22 and 20 yr, and 1 aunt, aged 36 yr, showed papillary thyroid carcinomas. The thyroid tumors were unique in 2 patients and multiple in the 22-yr-old woman. They were encapsulated and showed a predominant papillary architecture, with ground-glass nuclei and nuclear inclusions and grooves. One case (aged 20 yr) also had widespread follicular areas. Kindred 2 showed 2 patients, mother and daughter, affected by FAP. The 22-yr-old daughter, in addition to colonic polyposis, also had an 11-mm papillary thyroid carcinoma. apc mutations were demonstrated by direct sequencing of the PCR products. A 5-bp deletion around codon 1061 (A CAA A; position 3183-3187), creating a stop codon at position 3189 -3191, was observed in all of the affected patients of kindred 1, including the 3 patients carrying papillary thyroid carcinomas. In kindred 2, the apc mutation of the 2 affected members was at codon 1309 (22) (23) (24) .
Immunohistochemistry
Three-to 4-m paraffin sections were deparaffinized, placed in a solution of absolute methanol and 0.3% hydrogen peroxide for 30 min, and then treated with blocking serum for 20 min. The slides were incubated overnight at 4 C with affinity-purified antibodies specific for the ret tyrosine kinase domain (25, 26) , diluted 1:100, and subsequently incubated with biotinylated goat antirabbit IgG (Vectostain ABC kits, Vector Laboratories, Burlingame, CA) and with the premixed reagent, avidin-biotin-peroxidase complex (Vector) for 20 min. Immunostaining was performed with a diaminobenzidine (DAB; Dako, Carpenteria, CA) solution containing 0.06 mmol/L DAB and 2 mmol/L hydrogen peroxide. After chromogen development, the slides were counterstained with hematoxylin.
RT-PCR for ret/ptc expression
Ribonucleic acid (RNA) extraction from paraffin-embedded samples was performed as previously described (27) . Briefly, single 6-to 8-m tissue sections, cut from paraffin blocks, were stirred for 20 min in 1.5-mL tubes with 1 mL xylene. After centrifugation, the pellet was washed with 0.5 mL ethanol and air-dried. The dried pellet was resuspended in 200 L 6 mg/mL proteinase K (Sigma Chemical Co., St. Louis, MO), 1 mol/L guanidinium thiocyanate, 25 mmol/L 2-mercaptoethanol, 0.5% Sarkosyl, and 20 mmol/L Tris-HCl, pH 7.5, and incubated at 45 C for 6 h. RNA was then extracted with one sample equivalent volume of 70% phenol-30% chloroform, and the aqueous supernatant was transferred to a 0.5-mL tube containing 2 g glycogen. After adding 1 vol isopropanol, the supernatant was precipitated at Ϫ20 C overnight. After centrifugation for 15 min at 12,000 ϫ g in an Eppendorf (Barkhausenweg, Hamburg, Germany) microcentrifuge, the pellet was washed with 70% ethanol and air-dried. RT-PCR amplification was performed as previously reported (15) . The sequences of the forward primers used were: ret/ptc1, 5Ј-ATTGTCATCTCGCCGTTC-3Ј (nucleotides 196 -214) (18) ; ret/ptc2, 5Ј-TATCGCAGGAGAGACTGTGAT-3Ј (nucleotides 483-503) (19) ; and ret/ptc3, 5Ј-AAGCAAACCTGCCAGTGG-3Ј (nucleotides 697-714) (20) . The sequence of the reverse primer (synthesized according to the ret tyrosine kinase sequence) was 5Ј-TGCTTCAGGACGTTGAAC-3Ј (nucleotides 543-561) (18) . One fifth of the RNA was reverse transcribed using the reverse primer and, after addition of the forward primer, subjected to 40 cycles of PCR with a thermal cycler (Perkin-Elmer/Cetus, Norwalk, CT; 94 C for 30 min, 55 C for 2 min, and 72 C for 2 min ). The product of the reaction was analyzed on a 2% agarose gel and hybridized with a ret probe covering the tyrosine kinase domain. The human phosphoribosyl transferase gene (hprt)-specific primers were 5Ј-CCTGCTG-GATTACATCAAAGCACTG-3Ј (forward), corresponding to nucleotides 316 -340 of the third exon of the human gene; and 5Ј-CCTGAAGTATTCATTATAGTCTCAAGG-3Ј (reverse), corresponding to nucleotides 685-661 of the eighth exon of the human gene (28) .
Results
Three patients belonging to FAP kindred 1 (two 22-and 20-yr-old sisters, patients 1 and 2, and one 36-yr-old aunt, patient 3) and one patient (patient 4) of FAP kindred 2 had thyroid papillary carcinomas. Histological examination of these thyroid carcinomas was described in detail previously (22) . The families live in a region without iodine deficiency, and the patients had never had head or neck irradiation. To investigate ret/ptc activation in these tumors, we took advantage of the fact that ret expression is restricted to tissues and cell lines of neural crest origin. However, after the rearrangements generating ret/ptc oncogenes, ret regulatory sequences are replaced by those belonging to the genes fused to its tyrosine kinase domain. These genes (H4, RI, and RFG) are ubiquitously expressed, and thus, their promoters drive the expression of the truncated ret forms in thyroid cells. Indeed, we have previously demonstrated that the presence of Ret protein, detected by immunohistochemistry, correlates with ret/ptc activation in thyroid carcinomas found by RT-PCR analysis (29, 30) . We used this combined immunohistochemical and RT-PCR approach to analyze the four FAP-associated thyroid carcinomas for ret/ptc activation. The results of the immunohistochemical analysis, reported in Fig. 1 , demonstrated that the papillary carcinomas from the two sisters belonging to the FAP family (cases 1 and 2) were positive for ret/ptc expression; in contrast, the tumor of patient 3, was negative (Fig. 1D) . The papillary carcinoma in FAP patient 4 (kindred 2) also scored positive for ret/ptc expression (data not shown). Normal thyroid samples (no. 10), used as negative controls, did not show any ret/ptc expression (an example is shown in Fig. 1A) .
To confirm the expression of the rearranged ret version in the positive samples and to discriminate among the different forms of rearranged ret, the tumor samples were analyzed by RT-PCR using primers specific for ret/ptc1, -2, and -3 oncogenes. The three cases (patients 1, 2, and 4), which scored positive at the immunohistochemistry, showed a specific amplified fragment of 365 bp when ret/ptc1-specific primers were used ( Fig. 2A, lanes 5 and 6 , and data not shown). The sample (patient 3) negative at the immunohistochemistry was also negative at the RT-PCR (Fig. 2, lane 4) . As negative controls, RNA from normal thyroid (lane 1) and from a human papillary carcinoma previously scored negative for ret/ptc activation (lane 3) (15) were used. The positive control (lane 2) was represented by RNA extracted from the TPC cell line, which carries a ret/ptc1 oncogene (31). The quality of extracted RNA was confirmed by amplification with HPRT-specific primers (Fig. 2B) . No positivity was found in the examined samples for the other two ret/ptc isoforms (ret/ptc2 and ret/ptc3; data not shown). When the same RNAs were not reverse transcribed before PCR amplification, no amplified products were observed; this was used as a control to insure that the results were due to amplification of RNA and not to contaminating DNA (not shown).
Discussion
A predisposition to develop thyroid carcinomas has been observed in several kindreds affected by adenomatous polyposis coli (FAP). This suggests that mutations of the apc gene, when occurring in the germline (32, 33) , have the potential to predispose to development of thyroid carcinomas. Data reported in this manuscript demonstrate that ret/ptc1 activation is a genetic alteration that occurs in thyroid papillary carcinomas in some FAP patients. Germline apc mutations associate with at least other seven genetic alterations, including ras and p53 gene mutations in the development of colonic cancer (3). Sporadic papillary thyroid carcinomas are often characterized by ret activation (between 25-40% of the cases) (13) , and the group of FAP patients examined in this manuscript is not large enough to draw any firm statistical conclusion on the association between apc and ret gene mutations. However, to date, apc mutation is the first genetic alteration found in thyroid tumors in association with ret activation. One possibility to explain this association is that, in analogy to the scheme proposed for colon cancer progression, the two mutations may sequentially act in the establishment of some FAP-associated thyroid carcinomas. Although the frequent occurrence of ret/ptc in thyroid microcarcinomas might suggest that the rearrangement is an early event in thyroid tumorigenesis, the initiating or progressional nature of this genetic event is still unclear. The finding of somatic ret/ptc rearrangements in patients carrying a germ-line apc mutation suggests that they could be a progression event in neoplastic processes initiated by apc mutation. It will be worthwhile to investigate whether the two alterations cooperate in the neoplastic transformation of thyroid follicular cells. It is known that the ret/ptc oncoprotein has a constitutively activated kinase function, and thus, it is able to couple with mitogenic pathways (34) . On the other side, recent evidence indicates that apc product interacts with ␤-catenins and may modulate cellular adhesion and signaling pathways initiated by ␤-catenins (3). Experiments conducted with cultured thyroid cell lines or with transgenic mice will help to clarify this issue. Whatever the case, the excellent clinical behavior of FAP-associated thyroid carcinomas (4) (Cetta, F., in preparation) correlates with findings indicating that ret/ptc activation characterizes tumors that do not have a tendency to progress to an aggressive phenotype (Tallini, G., Santoro, M., Fusco, A., in preparation). No cytoplasmic staining was observed in the neoplastic cells. Three-to 4-m paraffin sections were deparaffinized, treated with diluted blocking serum for 20 min, and incubated overnight with affinity-purified antibodies specific for the ret tyrosine kinase domain (23) . The slides were subsequently incubated with biotinylated goat anti-rabbit IgG and then with the premixed reagent, avidin-biotin-peroxidase complex. Immunostaining was performed by incubating the slides in DAB solution. After chromogen development, the slides were washed, counterstained with hematoxylin, dehydrated with alcohol and xylene, and mounted with coverslips using a permanent mounting medium (Permount, Fisher Scientific, Fairlawn, NJ).
FIG. 2.
RT-PCR identification of ret/ptc1 expression. A, RNAs were amplified with ret/ptc1-specific primers, as indicated in the schematic diagram, subjected to electrophoretic separation on a 2% agarose gel, and hybridized with a ret probe covering its TK domain. Lane 1, A negative control represented by normal thyroid RNA; lane 2, a positive control represented by RNA extracted from the TPC cell line (31); lane 3, another negative control represented by RNA extracted from a thyroid tumor previously scored negative for ret/ptc1 activation (15); lanes 4 -6, RNAs extracted from FAP patients 3, 1, and 2, respectively. B, The same RNAs as those in A were subjected to RT-PCR amplification using HPRT-specific primers. The products of the amplification were run on a 2% agarose gel and hybridized to a HPRT-specific probe.
